Inhibikase Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Inhibikase Therapeutics, Inc. (IKT) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $5.35 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- Inhibikase Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $5.35M, a 27.02% increase year-over-year.
- Inhibikase Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $5.56M, a 172.24% increase year-over-year.
- Inhibikase Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $4.53M, a 2957.08% increase year-over-year.
- Inhibikase Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $4.21M, a 13610.60% increase year-over-year.
- Inhibikase Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $15.31M, a 88.07% increase from fiscal 2024.
- Inhibikase Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $8.14M, a 1527.64% increase from fiscal 2023.
- Inhibikase Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $500.15K, a 9.17% increase from fiscal 2022.
- Inhibikase Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $458.15K, a 70.09% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.35M 10-Q · filed 2026-08-11 | $10.91M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $5.56M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $15.31M 10-K · filed 2026-03-26 | |||
| 2025-09-30 | $4.53M 10-Q · filed 2025-11-14 | $8.73M derived: sum of 2 quarters · filed 2026-08-11 | $10.78M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $4.21M 10-Q · filed 2026-08-11 | $6.25M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $2.04M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $8.14M 10-K · filed 2026-03-26 | |||
| 2024-09-30 | $148.02K 10-Q · filed 2025-11-14 | $178.72K derived: sum of 2 quarters · filed 2025-11-14 | $232.16K derived: sum of 3 quarters · filed 2025-11-14 | |
| 2024-06-30 | $30.70K 10-Q · filed 2025-11-14 | $84.13K derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2024-03-31 | $53.43K 10-Q · filed 2025-11-14 | |||
| 2023-12-31 | $500.15K 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $129.78K 10-Q · filed 2024-11-14 | $254.63K derived: sum of 2 quarters · filed 2024-11-14 | $377.90K derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $124.84K 10-Q · filed 2024-11-14 | $248.12K derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $123.27K 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $458.15K 10-K · filed 2024-03-27 | |||
| 2022-09-30 | $101.79K 10-Q · filed 2023-11-14 | $234.56K derived: sum of 2 quarters · filed 2023-11-14 | $357.78K derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | $132.77K 10-Q · filed 2023-11-14 | $256.00K derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | $123.23K 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $1.53M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $352.42K 10-Q · filed 2022-11-14 | $674.90K derived: sum of 2 quarters · filed 2022-11-14 | $1.27M derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | $322.48K 10-Q · filed 2022-11-14 | $913.61K derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $591.12K 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $573.70K 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $139.76K 10-Q · filed 2021-11-15 | $279.52K derived: sum of 2 quarters · filed 2021-11-15 | $419.27K derived: sum of 3 quarters · filed 2021-11-15 | |
| 2020-06-30 | $139.76K 10-Q · filed 2021-11-15 | $279.52K derived: sum of 2 quarters · filed 2021-11-15 | ||
| 2020-03-31 | $139.76K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |